Breaking News

Catalent to Acquire MaSTherCell

Adds capabilities and technologies for the development and manufacture of autologous and allogeneic cell therapies, as well as related analytical services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent, Inc. has entered an agreement to acquire MaSTherCell Global, Inc., a technology-focused cell and gene therapy CDMO, for $315 million in cash, subject to customary adjustments. MaSTherCell offers a unique portfolio of capabilities and technologies that include the development and manufacture of autologous and allogeneic cell therapies, as well as a variety of related analytical services. Its experience includes therapies based on chimeric antibody receptor-engineered T cells (CAR-T), T ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters